Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: Hematol Oncol Stem Cell Ther. 2020 May 15;14(1):33–40. doi: 10.1016/j.hemonc.2020.05.002

Table 2.

Risk of Bias in Included Studies.

Study Representativeness of the cohort Ascertainment of exposure Demonstration that outcome of interest was not present at start of study Assessment of outcome Was follow-up long enough for outcomes to occur? Adequacy of follow up of cohorts
Tsimberidou et al. 2006 [14] Low risk Low risk Low risk Low risk Low risk Low risk
Cwynarski et al. 2012 [31] Unclear/High risk Low risk Low risk Low risk Low risk Low risk
Rozovski et al. 2015 [30] Low risk Low risk Low risk Low risk Low risk Low risk
Kharfan-Dabaja et al. 2017 [29] Low risk Low risk Low risk Low risk Low risk Low risk